IMUNON Announces Strategic Sale of ThermoDox®
Globe Newswire•21/10/2026•08:15 ET
0
Key Highlights
- ➤IMUNON sells ThermoDox rights to VoxelDox for equity, milestones, and royalties
- ➤IMUNON receives approximately 4.76% equity in VoxelDox after financing closes
- ➤IMUNON could receive up to $16.5 million in development and sales milestones
- ➤ThermoDox royalties range from 3.5% to 6% on net sales if approved
- ➤Transaction closing depends on VoxelDox completing a planned $2.5 million financing
Expert Statements
Stacy R. Lindborg, President and Chief Executive Officer of IMUNON
“We are pleased that ThermoDox has found a steward committed to advancing its development for the benefit of patients.”
Stacy R. Lindborg, President and Chief Executive Officer of IMUNON
“This agreement is consistent with our previously announced strategy to identify a development partner for this promising drug candidate and demonstrates our disciplined approach to portfolio management and capital allocation.”
Stacy R. Lindborg, President and Chief Executive Officer of IMUNON
“By creating a path to realize future value from a legacy asset that has been fully written off, the transaction allows our organization to remain singularly focused on the successful execution of the pivotal Phase 3 OVATION 3 trial of IMNN-001 in frontline advanced ovarian cancer.”
Stacy R. Lindborg, President and Chief Executive Officer of IMUNON
“We look forward to following VoxelDox’s progress as it works to advance this technology for patients with glioblastoma.”
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
Sale Reinforces IMUNON's Commitment to Its Core Strategy: Executing the Pivotal Phase 3 OVATION 3 Trial of IMNN-001
Get started
Create a free account to read the full story.